# Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT04892446** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 36 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Magrolimab
- **DRUG:** Daratumumab
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Bortezomib
- **DRUG:** Carfilzomib

## Key facts

- **NCT ID:** NCT04892446
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-09
- **Primary completion:** 2024-04-25
- **Final completion:** 2024-04-25
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and close the program.
- **Last updated:** 2025-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04892446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04892446, "Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04892446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*